Integer (ITGR) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales grew 9% year-over-year to $436 million, with organic growth of 5% and strong Medical segment performance offsetting Non-Medical declines.

• Adjusted operating income rose 20% to $55.2 million, and adjusted EPS increased 14% to $1.30; GAAP net income was $31.2 million, up 30%.

• Gross margin improved by 100 bps to 27.4%, supported by manufacturing efficiencies and higher volume.

• Full-year profit outlook was raised, with above-market sales growth, expanding margins, and robust order book.

• Free cash flow guidance for 2024 set at $85–$105 million.

Financial highlights

• Q2 2024 sales reached $436 million (+9% YoY, 5% organic); adjusted EBITDA was $91 million (+19% YoY); adjusted net income was $45 million (+17% YoY).

• Adjusted EPS for Q2 was $1.30, up from $1.14 in Q2 2023; GAAP diluted EPS was $0.88.

• Free cash flow in Q2 ranged from $16 million to $37 million, primarily used to reduce net total debt.

• Cash flow from operations in Q2 was $62 million; six-month sales reached $851 million (+9.3% YoY).

• Net total debt at quarter-end was $950 million to $1.097 billion; leverage ratio at 3.2x trailing adjusted EBITDA.

Outlook and guidance

• 2024 sales expected at $1.735–$1.77 billion, up 9%–11% year-over-year; organic growth 6%–8%.

• Adjusted operating income outlook raised to $275–$293 million (14%–21% growth); adjusted EBITDA expected at $357–$377 million.

• Adjusted EPS guidance for 2024 is $5.07–$5.49 (9%–18% growth); adjusted effective tax rate projected at 18%–20%.

• Free cash flow projected at $85–$105 million; CapEx at $90–$110 million.

• Year-end leverage ratio targeted within 2.5x–3.5x.